Valuation : Simulations Plus, Inc.

Market Cap 373M 321M 302M 276M 516M 35.21B 517M 3.57B 1.38B 18.05B 1.4B 1.37B 58.18B P/E 2026 *
43.9x
P/E 2027 * 40.3x
Enterprise Value 373M 321M 302M 276M 516M 35.21B 517M 3.57B 1.38B 18.05B 1.4B 1.37B 58.18B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 4.32x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
1 month-0.63%
3 months+8.97%
6 months+49.06%
1 week 15.8
Extreme 15.8
15.8
1 month 15.7
Extreme 15.7
15.9
Manager TitleAgeSince
Chief Executive Officer 67 25/06/2018
Director of Finance/CFO 63 30/11/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 16/07/1996
Director/Board Member 58 02/12/2014
Chairman 76 16/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 373M
-3.27%-0.58%+0.79%+23.65% 44.54B
+0.72%-4.15%-41.67%+137.77% 13.1B
-0.14%+0.97%-12.21%+91.43% 5.85B
-1.61%+2.37%+57.42% - 4.25B
+0.31%+6.91% - - 2.1B
-1.29%+3.90%+7.04%-41.73% 1.57B
+1.43%-4.31%-32.99% - 1.1B
+0.59%+1.58%+22.62%+147.60% 1.02B
-5.69%-5.39%+41.60%+46.92% 931M
Average -0.99%+0.01%+5.32%+67.61% 8.27B
Weighted average by Cap. -1.99%-0.71%-4.16%+52.56%

Financials

2026 *2027 *
Net sales 81.87M 70.49M 66.3M 60.56M 113M 7.73B 114M 784M 304M 3.97B 307M 301M 12.78B 86.26M 74.26M 69.85M 63.8M 119M 8.15B 120M 826M 320M 4.18B 324M 317M 13.46B
Net income 9.53M 8.21M 7.72M 7.05M 13.19M 901M 13.23M 91.24M 35.38M 462M 35.8M 35.02M 1.49B 10.18M 8.77M 8.24M 7.53M 14.08M 962M 14.13M 97.44M 37.78M 493M 38.23M 37.4M 1.59B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
-
Date Price Change
04/09/26 €15.80 0.00%
03/09/26 €15.80 0.00%
02/09/26 €15.80 0.00%
01/09/26 €15.80 0.00%
31/08/26 €15.80 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.43USD
Average target price
17.25USD
Spread / Average Target
-6.40%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!